J&J in advanced talks to buy Crucell
This article was originally published in Scrip
Executive Summary
J&J is in advanced negotiations to pay €1.75 billion ($2.3 billion) for all the outstanding shares of the Dutch biotechnology company Crucell, of which it already owns almost 18%.